tbuckley/cabot-search huggingface dataset:
ABSENCE OF CLINICAL TRIGGERING IN DIABETIC PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION PREDICTS MULTIPLE VESSEL CORONARY DISEASE AND IS ASSOCIATED WITH INCREASED MORTALITY
Authors: Jeremy Ben-Shoshan, David Zahler, Yafit Segman-Rosenstveig, Yaron Arbel, Ehud Chorin, Michael Barkagan, Zach Rozenbaum, Yoav Granot, Ariel Finkelstein, Shmuel Banai, Gad Keren, Yacov Shacham, Maayan Konigstein
Journal: Journal of the American College of Cardiology (2017)
FIVE YEAR OUTCOMES OF FRACTIONAL FLOW RESERVE GUIDED VERSUS INTRAVASCULAR ULTRASOUND GUIDED PERCUTANEOUS CORONARY INTERVENTION IN INTERMEDIATE CORONARY ARTERY DISEASE
Authors: Yunkyeong Cho, Hyoung-Seob Park, Hyuck Jun Yoon, Hyungseop Kim, Chang-Wook Nam, Seongwook Han, Seung-Ho Hur, Yoon-Nyun Kim, Kwon-Bae Kim
Journal: Journal of the American College of Cardiology (2017)
Changes in patient-reported outcomes in patients diagnosed with and treated for multiple myeloma in the Connect MM registry.
Authors: Chris L. Pashos, Jatin J. Shah, Howard R. Terebelo, Brian G. Durie, Rafat Abonour, Cristina Gasparetto, Jayesh Mehta, Mohit Narang, Sachdev Thomas, Kathleen Toomey, Arlene S. Swern, Kristen A. Sullivan, Thomas K. Street, Zeba M. Khan, Ali Nourbakhsh, James Hardin, Tanya Marya Wildes, Robert M. Rifkin
Journal: Journal of Clinical Oncology (2013)

8586 Background: Little is known about the impact of treatment on patient-reported outcomes (PROs) and health-related quality of life (HRQoL) in multiple myeloma (MM) patients (pts). The change in PROs of MM pts between baseline and 1 year was assessed relative to their baseline International Staging System (ISS) stage and Eastern Cooperative Oncology Group (ECOG) performance status (PS) score. Methods: Connect MM is a prospective US registry of MM pts initiated in 2009. Clinicians reported pt demographics, ECOG PS score, and ISS stage. PROs were collected at baseline and at 1 year utilizing the Functional Assessment of Cancer Therapy (FACT)-MM, EQ-5D, and Brief Pain Inventory (BPI). Changes in FACT-MM, EQ-5D, and BPI scores were analyzed by ISS stage and ECOG PS score in 636 pts meeting CRAB criteria from 189 centers. Results: Most pts were male (58%) and white (84%). Mean age was 66 years (± 11). Pts were treated in community (81%), academic (17%), or veterans/military (2%) settings. ISS stages of pts were: I (29%), II (35%), and III (35%). ECOG PS scores were 0 (37%), 1 (49%), 2 (11%), and 3 (3%). Improvements in overall HRQoL as shown by the FACT-MM and FACT-General (G) total scores, were observed across all ISS stages (P = 0.03 to &lt; 0.0001) with no significant differences between stages. Improvements in FACT-MM and FACT-G total scores were observed with ECOG PS scores 1–3 (P = 0.03 to 0.005). Pts with poorer ECOG PS scores tended to have greater improvement in EQ-5D domains of mobility, self-care, and usual activities. HRQoL/functional ability improved in 4 of 5 FACT domains (except social/family; all others P &lt; 0.0001), and in 4 of 5 EQ-5D domains (except pain/discomfort; all others, P = 0.01 to &lt; 0.0001). BPI showed that overall average pain improved (P &lt; 0.0005) over 1 year, but statistically significant differences by ISS stage or ECOG PS score were not observed. Conclusions: Connect MM data showed that overall HRQoL of MM pts improved between baseline and 1 year, with a consistent benefit observed across pts with different ISS stages and ECOG PS scores. Additional analysis should examine which disease- and treatment-related factors are associated with these HRQoL improvements.
Rapamycin Analogs Reduce mTORC2 Signaling and Inhibit AKT Activation in AML.
Authors: Zhihong Zeng, Dos D. Sarbassov, Francis J. Giles, Ismael Samudio, Karen W.L. Yee, C. Ellen Jackson, David M. Sabatini, Michael Andreeff, Marina Konopleva
Journal: Blood (2006)
Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer (MBC) treated with bevacizumab and weekly paclitaxel (Bev-Pac).
Authors: Andrés Redondo, Marta Mendiola, Virginia Martínez-Marín, Jesus Herranz, Laura Yebenes, Beatriz Castelo, Pilar Zamora, Alvaro Pinto, Patricia Cruz, Victoria Heredia, Esther Diaz, Angelo Gámez-Pozo, Juan Angel Fresno-Vara, Ana Ramirez de Molina, David Hardisson, Enrique Espinosa
Journal: Journal of Clinical Oncology (2014)

564 Background: The combination of Bev-Pac significantly improved progression-free survival (PFS), compared with Pac alone in first-line treatment of HER2-negative MBC. To date only a few biomarkers relating to bevacizumab efficacy have been published, and none of them have been validated in prospective studies. The aim of this study is to build a profile predicting PFS in patients treated with Bev-Pac. Methods: 60 patients with Her2-negative MBC treated with Bev-Pac were included. RNAs were collected from formalin-fixed paraffin-embedded primary breast samples. Expression levels of 170 angiogenesis related genes were measured using quantitative real time PCR. Predictive models, genetic (G) and combined genetic-clinical (GC), were fitted by Lasso-penalized multivariate Cox proportional hazards modeling and validated by Leave One Out Cross Validation (LOOCV). Cross-validated Kaplan-Meier (KM) curves and time-dependent ROC curves were generated to estimate the predictive accuracy of the PFS models, and a log-rank permutation test was used to evaluate the statistical significance. Results: 49 patients had estrogen positive, and 11 had triple negative tumors. 60% received Bev-Pac in first line, and 40% in second or subsequent lines. Median PFS was 11.4 months. The multivariate clinical model generated with 5 variables (number of previous lines, disease free interval, estrogen receptor status, previous chemotherapy and metastatic locations) showed the last one (< 3 vs > 3 locations or liver metastasis) as the only clinical variable significantly correlated with PFS. An 11-gene profile (G model) was correlated with PFS. The G model and the GC model identified two groups of patients with different PFS, although the GC model was statistically more consistent across different time points (median PFS 17.9 months in favorable group vs. 7.4 months in the other). Conclusions: A molecular signature of 11 genes correlated with PFS in a series of patients treated with Bev-Pac. Better predictive accuracy was obtained by a combination of genetic and clinical variables.
THE MIXED RACE ATHLETE'S ECG: NOT SO BLACK AND WHITE
Authors: Aneil Malhotra, Prashant Rao, Harshil Dhutia, Sabiha Gati, Tee Joo Yeo, Rajit Khosla, Vivek Prasad, Michael Papadakis, Sanjay Sharma
Journal: Journal of the American College of Cardiology (2017)
QUANTITATIVE MEASUREMENTS ON CARDIAC MAGNETIC RESONANCE TO DIFFERENTIATE BENIGN VERSUS MALIGNANT MASSES: A PILOT STUDY
Authors: Hilda Mariana Gonzalez Bonilla, Mohamamd Khan, Eric Yang, Akanksha Thakkar, Bader Alshammari, Roberto Barrios, Faisal Nabi, Michael Reardon, Dipan Shah
Journal: Journal of the American College of Cardiology (2017)
Impact of palifermin use on pediatric patient (PedPts) hematopoietic cell transplant (HCT) outcomes.
Authors: Wael Saber, Patricia Steinert, Mei-Jie Zhang, Min Chen, Mary M. Horowitz
Journal: Journal of Clinical Oncology (2014)

7117 Background: Palifermin (KGF) is an FDA approved prophylactic human keratinocyte growth factor for prevention of severe chemoradiotherapy-related mucositis. Clinical trials that evaluated KGF enrolled few PedPts. Using CIBMTR data, this study evaluates effects of KGF use in a pediatric population. Methods: We performed a 1:3 (KGF vs. no KGF) matched cohort analysis (matched on HCT, donor type, disease, disease status and age). Stratified Cox models were built and propensity scores were used to adjust for potential confounders. Results: From 2005-2012 816 patients were selected; 60% underwent Allogeneic HCT (AlloHCT), mostly for acute lymphoblastic leukemia (ALL). 40% underwent Autologous HCT (AutoHCT), mostly for solid tumors (Table 1). Two-year survival (OS) and disease-free survival (DFS) in AlloHCT group (58 vs. 66%, p=0.10; 49% vs. 60%, p=0.06) and AutoHCT group (73% vs. 77%, p=0.47; 60% vs. 64%, p=0.63) were not different between KGF and no KGF, respectively. Similarly, in multivariate analysis, there were no differences in outcomes between the two groups. Conclusions: Among PedPts undergoing HCT, KGF use is not associated with OS, DFS, neutrophil recovery or graft vs host disease (GVHD) rates. Due to data limitations, rate of mucositis was not assessed in this study. KGF N (%) No KGF N (%) N 210 606 Age, yrs 9 (<1 - 18) 9 (<1 - 18) Disease AML 27 (13) 78 (13) ALL 86 (41) 252 (42) NHL 13 ( 6) 35 ( 6) Hodgkin disease 15 ( 7) 42 ( 7) Solid Tumors 69 (33) 199 (33) Donor (AlloHCT) HLA-identical sibling 33 (16) 97 (16) Other related 5 (2) 15 (2) Match Unrelated 24 (11) 72 (12) Mismatch Unrelated 29 (14) 79 (13) Cord blood 29 (14) 86 (14) Conditioning regimen* AutoHCT: BEAM 40 (44) 153 (60) AlloHCT: TBI+others 105 (88) 298 (85) Median follow-up of survivors, m 31 36 KGF (yes vs. no) RR (95% CI) P AlloHCT only: Acute GVHD, II-IV 1.19 (0.79-1.80) 0.40 Chronic GVHD 0.66 (0.39-1.10) 0.11 AlloHCT and AutoHCT: Neutrophil recovery 1.20 (0.98-1.48) 0.08 DFS 1.14 (0.84-1.53) 0.39 OS 1.20 (0.87-1.66) 0.27 *Largest group provided
Mechanism of Acadesine-Induced Apoptosis in B-Cell Neoplasms.
Authors: Antonio F. Santidrián, Clara Campàs, Llorenç Coll-Mulet, Daniel Iglesias-Serret, Ana M. Cosialls, Mercé Defrias, Alicia Domindo, Alberto Fernandez de Sevilla, Gabriel Pons, Joan Gil
Journal: Blood (2005)
Blood vessel invasion (BVI) in curatively (R0) resected stage II and IIIA non-small cell lung (NSCLC) cancer patients.
Authors: Wolfgang M. Brueckl, Dieter Wuerflein, Dietmar Kraus, Christian Meyer, Manfred Wagner, Joachim H Ficker
Journal: Journal of Clinical Oncology (2012)

e17536 Background: A single center study was conducted to identify the prognostic and predictive value of blood vessel invasion (BVI) in surgically R0 resected stage II and IIIA non-small cell lung cancer patients. Methods: A total of N=105 consecutive patients who had undergone complete (R0) resection for stage II/IIIA primary non-small cell lung cancer (NSCLC) between 01/2008 and 12/2010 at the Lung Cancer Center Nuremberg were evaluated. All pathological specimens were examined for evidence of BVI. All patients were followed for tumour recurrence and survival. Differences between groups were calculated with Chi-square test. Recurrence and survival data were analyzed for all patients using Kaplan-Meier test. Significance was univaratiately calculated by log-rank and multivariately by Cox-regression analysis. Results: The baseline clinical data showed no significant differences between patients with adjuvant chemotherapy (aCTx; cisplatin/vinorelbine; N=46) and without aCTx (N=59) beside of age (aCTx treated patients were younger p=0.03). Demographic data were as follows: male 64%; age &lt;65 years 53%; ECOG 0/1/2 (47%/35%/3%); histology AC/SCC/other (53%/37%/10%); stage IIA/IIB/IIIA (13%/31%/55%); BVI 29%; pneumonectomy 19%. ECOG-PS 0 and no BVI were positive prognostic factors for both recurrence free survival (RFS) and overall survival (OS) in the group without aCTx and remained independent prognostic factors in the multivariate analysis (p&lt;0.001; p=0.002). Additionally, ECOG-PS 0 and no BVI were independent predictive factors for RFS and OS in the aCTx treated group. Conclusions: BVI is an independent prognostic and predictive factor in R0 resected stage II/IIIA NSCLC patients. This subset of patients may have a greater benefit from aCTx and may need to be followed-up more closely.
TRATAMIENTO DE LA COLECISTITIS AGUDA MEDIANTE COLOCACIÓN DE DRENAJE COLECISTODUODENAL TRANSPAPILAR EN PACIENTES DE ALTO RIESGO QUIRÚRGICO
Authors: B Moreira, A Germade, L Pérez, R Castillo, K De Jesús, S Maestro, F Santos, F Igea, J Barcenilla, A Pérez, E Saracibar, R Madrigal, A Santamaria
Journal: Endoscopy (2015)

Introducción: La colecistitis aguda es una enfermedad común, tratada mayoritariamente de forma quirúrgica. Sin embargo, la intervención quirúrgica urgente en pacientes mayores, con múltiples comorbilidades, puede aumentar la morbimortalidad. En estos pacientes, el drenaje vesicular puede ser una medida temporaria o tratamiento definitivo.
GENERAL POPULATION SCREENING FOR SUDDEN CARDIAC DEATH IN YOUNG INDIVIDUALS: IS IT FEASIBLE, IS IT JUSTIFIABLE &amp; HOW MUCH DOES IT COST?
Authors: Navin Chandra, Mohamad Barakat, Harshil Dhutia, Michael Papadakis, Rachel Bastiaenen, Sanjay Sharma
Journal: Journal of the American College of Cardiology (2017)
P-Loop an T315I BCR-ABL Mutations in Chronic Myelogenous Leukemia (CML) Patients Are of Poor Prognosis, but the Y253H + E255K P-Loop Mutations Are of Even More Severe Prognosis in Chronic Phase. On the Behalf of the French Intergroup of CML (Fi-LMC Group).
Authors: Franck E. Nicolini, Sélim Corm, Quoc-Hung Lê, Sandrine Hayette, Nathalie Sorel, Dominique Bories, Stéphane Giraudier, Michel Tulliez, Philippe Rousselot, Jean-Michel Cayuela, François-Xavier Mahon, Pascale Cony-Makhoul, Jean-Jacques Kiladjian, Olivier Tournilhac, François Guilhot, Catherine Roche-Lestienne, Claude Preudhomme, Mauricette Michallet
Journal: Blood (2005)
Phase 2 Multicenter Trial of Oral Quisinostat, a Histone Deacetylase Inhibitor, in Patients with Previously Treated Stage IB-IVA Cutaneous T-Cell Lymphoma
Authors: Fiona Child, Pablo Ortiz Romero, Rute Alvarez, Martine Bagot, Rudolf Stadler, Michael Weichenthal, Rosario Alves, Maria Grazia Bernengo, Marie Beylot-Barry, Richard Cowan, Larisa J. Geskin, Amparo Pérez Ferriols, Peter Hellemans, Yusri Elsayed, Charles Phelps, Ann Forslund, Makio Kamida, Pier Luigi Zinzani
Journal: Blood (2012)
UTILIZATION OF DISTAL EMBOLIC PROTECTION IN INFRAINGUINAL PERIPHERAL ARTERIAL INTERVENTION: INSIGHTS FROM THE MULTICENTER XLPAD REGISTRY
Authors: Houman Khalili, Haekyung Jeon-Slaughter, Ishita Tejani, Amutharani Baskar, Ehrin Armstrong, Nicolas Shammas, Andrew Shammas, Anand Prasad, Ian Cawich, Gerardo Rodriguez, Mazen Abu-Fadel, Emmanouil Brilakis, Subhash Banerjee
Journal: Journal of the American College of Cardiology (2017)
Risk of grand mal status epilepticus in primary malignant brain tumor patients treated with anti-neoplastic therapy.
Authors: Tapan Mehta, Sonam Puri, Parshva Patel, Khushboo Sheth, Jitesh Joshi, James J. Vredenburgh
Journal: Journal of Clinical Oncology (2015)

e13018 Background: Epileptic seizures are common and a potentially debilitating complication in patients with primary malignant brain tumors (PMBT). They are more common in patients with PMBT compared to patients with benign brain tumors and secondary metastatic brain lesions. Antiepileptic drugs (AED) are routinely used in treatment of seizures in this population. In this nationwide study, we investigated the risk of grand mal status epilepticus in patients with PMBT treated with chemotherapy. Methods: We queried the Nationwide Inpatient Sample (NIS) database from 2002 and 2011 and identified the hospitalizations due to or with PMBT using respective ICD 9 diagnostic codes. We compared the risk of grand mal status epilepticus in PMBT population using multivariate logistic regression. The regression model included demographics (age, sex, and race) and clinically relevant covariates (hypertension, ischemic stroke, intracranial bleed, craniotomy, radiation therapy, hyponatremia, intracranial infections, brain neoplasms other than PMBT, and alcohol use). Using SAS 9.2, survey procedures were used to identify multivariate predictors of grand mal status epilepticus. Results: A total of 633,356 hospitalizations with PMBT were identified, of which 5,112 had grand mal status epilepticus. Mean age of PMBT patients with grand mal status epilepticus was 49.3 years with 57.7% males. Chemotherapy was an independent predictor of grand mal status epilepticus in PMBT patients (adjusted odds ratio 2.14, 95% confidence interval 1.41 -3.25, p = 0.0004). However, treatment with radiation therapy was not a predictor of grand mal status epilepticus in this population. Conclusions: We found that exposure to chemotherapy in patients with PMBT was an independent predictor of status epilepticus. There is paucity of data on the efficacy of different AED in patients with PMBT in the setting of chemotherapy. Our results highlight the potential AED-chemotherapy drug interactions which have been previously reported in literature with use of hepatic isoenzyme inducing AEDs. Clinicians should consider these interactions while prescribing and monitoring AEDs in this patient population.
Chronic Graft-Versus-Host Disease in Double Cord Blood Transplantation According to National Institutes of Health 2005 Criteria: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party of the EBMT
Authors: Hiromi Hayashi, Annalisa Ruggeri, Hanadi Rafii - El Ayoubi, Jan J. Cornelissen, Gerard Socié, Niels S. Andersen, Mauricette Michallet, Dimitrios Karakasis, Eefke Petersen, Joan Hendrik Veelken, Jean Yves Cahn, Pierre-Simon Rohrlich, Melanie Mercier, Fernanda Volt, Chantal Kenzey, Erick Xavier, Vanderson Rocha, Eliane Gluckman
Journal: Blood (2016)
Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin
Authors: Martin Metz, Petra Staubach, Andrea Bauer, Randolf Brehler, Janine Gericke, Michael Kangas, Joanna Ashton-Chess, Philip Jarvis, Panayiotis Georgiou, Janice Canvin, Rainer Hillenbrand, Veit J. Erpenbeck, Marcus Maurer
Journal: Theranostics (2017)

Background.Treatment with omalizumab, a humanized recombinant monoclonal anti-IgE antibody, results in clinical efficacy in patients with Chronic Spontaneous Urticaria (CSU).The mechanism of action of omalizumab in CSU has not been elucidated in detail. Objectives.To determine the effects of omalizumab on levels of high affinity IgE receptor-positive (FcεRI + ) and IgE-positive (IgE + ) dermal cells and blood basophils.Treatment efficacy and safety were also assessed.Study design.In a double-blind study, CSU patients aged 18-75 years were randomized to receive 300 mg omalizumab (n=20) or placebo (n=10) subcutaneously every 4 weeks for 12 weeks.Changes in disease activity were assessed by use of the weekly Urticaria Activity Score (UAS7).Circulating IgE levels, basophil numbers and levels of expression of FcεRI + and IgE + cells in the skin and in blood basophils were determined.Results.Patients receiving omalizumab showed a significantly greater decrease in UAS7 compared with patients receiving placebo.At Week 12 the mean difference in UAS7 between treatment groups was -14.82 (p=0.0027),consistent with previous studies.Total IgE levels in serum were increased after omalizumab treatment and remained elevated up to Week 12. Free IgE levels decreased after omalizumab treatment.Mean levels of FcεRI + skin cells in patients treated with omalizumab 300 mg were decreased at Week 12 compared with baseline in the dermis of both non-lesional and lesional skin, reaching levels comparable with those seen in healthy volunteers (HVs).There were no statistically significant changes in mean FcɛRI + cell levels in the placebo group.Similar results were seen for changes in IgE + cells, although the changes were not statistically significant.The level of peripheral blood basophils increased immediately after treatment start and returned to Baseline values after the follow-up period.The levels of FcεRI and IgE expression on peripheral blood basophils were rapidly reduced by omalizumab treatment up to Week 12. Conclusions.Treatment with omalizumab resulted in rapid clinical benefits in patients with CSU.Treatment with omalizumab was associated with reduction in Fcɛ RI + and IgE + basophils and intradermal cells.
FIRST CASE ON BIVENTRICULAR MECHANICAL CIRCULATORY SUPPORT WITH IMPELLA CP AND IMPELLA RP FOR A PATIENT WITH ACUTE MYOCARDIAL INFARCTION INDUCED CARDIOGENIC SHOCK
Authors: Xiangke Huang, Rehan Kahloon, Charles Campbell, Alison Bailey, Harish Manyam
Journal: Journal of the American College of Cardiology (2017)
MULTIPLE BIOMARKERS FOR PREDICTING MAJOR ADVERSE CARDIAC EVENTS IN AT-RISK PATIENTS UNDERGOING DIAGNOSTIC CORONARY ANGIOGRAPHY: RESULTS FROM THE CATHETER SAMPLED BLOOD ARCHIVE IN CARDIOVASCULAR DISEASES (CASABLANCA) STUDY
Authors: Cian McCarthy, Roland Van Kimmenade, Hanna Gaggin, Mandy Simon, Nasrien Ibrahim, Parul Gandhi, Noreen Kelly, Arianna Belcher, Shweta Motiwala, Rhonda Rhyne, Craig Magaret, James Januzzi
Journal: Journal of the American College of Cardiology (2017)
BMA criticises plan to make new doctors work in NHS for at least five years
Authors: Matthew Limb
Journal: BMJ (2017)

Doctors’ leaders have criticised government plans that could see doctors being forced to work in the NHS for at least five years after completing their training in England. Ministers proposed the idea in a consultation on expanding the medical workforce, launched on Tuesday 14 March.1

Doctors might also have to pay back some of their training costs if they did not stay in the NHS, as part of a “return of service agreement” that could mirror the system used in the armed forces.

England’s health secretary, Jeremy Hunt, said that increasing the supply of “home grown” clinicians would help to create a “self sufficient” workforce, easing reliance on agency staff and doctors from …
Allogeneic Stem Cell Transplantation for Relapsed / Refractory (R/R) Follicular Lymphoma (FL). a Joint Study Between the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR)
Authors: Anna Sureda, Mei-Jie Zhang, Peter Dreger, Jeanette Carreras, Timothy S. Fenske, Herve Finel, Harry C. Schouten, Silvia Montoto, Stephen Robinson, Sonali M. Smith, Ariane Boumendil, Mehdi Hamadani, Marcelo C. Pasquini
Journal: Blood (2015)
Osteonecrosis of the jaw and bisphosphonate therapy: Experience from a single Italian institution
Authors: E. Collovà, S. Paulli, M. Morabito, D. Frattini, O. Martelli, S. Fava
Journal: Journal of Clinical Oncology (2007)

19661 Background: Osteonecrosis of the jaw (ONJ) is reported as serious side-effect after bisphosphonate (B) therapy. Although the number of patients (pts) presenting with ONJ seems to be increasing, the exact prevalence and etiology of osteonecrosis are not well established because of heterogeneous of clinical reports. Methods: From May 2005 and October 2006, 12 cases of ONJ were diagnoses at our Institution. Results: Characteristics of patients: the median age at presentation of ONJ was 64.2 years (range 43–79); 9 pts were female and 3 pts were male. All pts were treated with Zoledronic acid, none of pts were pretreated with other B. Location of necrosis was mandible and maxilla. Presenting symptoms were: parondotosis disease, bone exposure and ulceration. Osteonecrosis was preceded by dental extraction in 5 pts (45%). The diagnosis of ONJ was: clinical (exposed bone) and radiological in all pts; the biopsy was performed in 3 pts, none of wich showed the presence of neoplastic disease. The treatments of ONJ were: antibiotic in 3 pts, partial maxillectomiy in 2 pts, curettage in 8 pts. Only 1 pts was documented residual sites of necrosis after surgical malignancies. All pts are alive at the time of this report, with except of one. Characteristics of malignancies: breast cancer 7 pts, prostate cancer 2 pts, multiple myeloma 1 pts, carcinoma of unknown primary 1 pts. Concomitant or previous therapies for malignancies were: chemotherapy and/or radiotherapy in all pts. None of pts received radiotherapy to the involved region. B therapy has been continued in about half pts, irrespective previously ONJ, without worsening clinical condition. Conclusions: In our experience the number of pts with previous history of dental extraction and subsequent ONJ during B therapy is consistent as described in many reports. This condition may represent an important risk factor for developing osteonecrosis correlated with prolonged infusion of B. In order to reduce incidence and serious side effects of B therapy, we adopted alternative schedule treatment with bi or tri - monthly infusion. No significant financial relationships to disclose.